Glucagon-like peptide 1 and type 1 diabetes: NOD ready for prime time?
Hadjiyanni
Irene
I
Department of Medicine, Samuel Lunenfeld Research Institute, Mt Sinai Hospital, SLRI 975C, Toronto, Ontario, Canada.
Drucker
Daniel J
DJ
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D017252:CD3 Complex / Q000276:immunology; D003131:Combined Modality Therapy; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology* / Q000628:therapy*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000502:physiology*; D000067757:Glucagon-Like Peptide-1 Receptor; D007167:Immunotherapy; D051379:Mice; D016688:Mice, Inbred NOD; D008954:Models, Biological; D010455:Peptides / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use
D000906:Antibodies; D017252:CD3 Complex; C000593834:Glp1r protein, mouse; D000067757:Glucagon-Like Peptide-1 Receptor; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide